1M. Pharm, MBA (NMIMS), Business Development at BIBO HEALTH (Hilt Brands India Pvt Ltd), Bengaluru.
2B. Pharmacy (PESCP), B2B Sales at BIBO HEALTH (Hilt Brands India Pvt Ltd), Bengaluru.
3MBA (IIT), CEO and Co-Founder at BIBO HEALTH (Hilt Brands India Pvt Ltd), Bengaluru.
The use of pharmacological treatment for COPD has increased over the past few decades and paints a positive image. In COPD, methylxanthines are frequently utilised. Theophylline is a well-known bronchodilator and anti-inflammatory drug, whilst Acebrophylline is a more recent addition in modern respiratory treatment, both are utilised as supplemental therapies for stable COPD patients using LAMA (long-acting muscarinic antagonists). Acebrophylline has anti-inflammatory properties and regulates airway mucus. The drug's strategy for treating obstructive airway disease incorporates numerous points of attack. Theophylline-7 acetic acid, whose carrier role elevates blood levels of Ambroxol, stimulates surfactant formation quickly and intensively. The molecule includes Ambroxol, which promotes several processes in the creation of pulmonary surfactants. Ciliary clearance is significantly improved as a result of the mucus' reduced viscosity and adhesivity. Acebrophylline also exerts an anti-inflammatory effect by diverting phosphatidylcholine toward the manufacture of surfactants, which prevents it from being used for the production of inflammatory mediators like leukotrienes.
Sourav Pattanayak, Sagar Sheel, Vikash Kumar, Acebrophylline Is A Better Choice Of Drug Over Theophylline For Patients With Asthma, COPD And Bronchitis Patients, Int. J. in Pharm. Sci., 2023, Vol 1, Issue 9, 403-411. https://doi.org/10.5281/zenodo.8372371